Thalidomide, Prolyl Hydroxylase, Collagen Biosynthesis, Complement Activation, Suppressive Therapy
Introduction
The enzymatic post-translational conversion of genetically coded amino acid residues, standard for all proteins, to uncoded amino acid residues, speci fic for specialized molecules, is fundamental for structure and function of many proteins and hor mones. Intentional intervention on certain modifica tions represents an essential part of pharmacology and is customary in therapy: The antithyroid drugs inhibit iodination of thyrosyl to 3-or 5-monoiodothyrosyl or 3,5-diiodothyrosyl residues within thyroglobulin1'2, the oral anticoagulants suppress vitamin K-dependent carboxylation of glutamyl to 4-carboxyglutamyl residues within Factors II, VII, IX, x 3-8.
We interpret the established non-sedative actions of thalidomide in man as an unintentional inter ference with the hydroxylation of prolyl residues (Pro) to frans-4-hydroxyprolyl residues (Hyp).
Hyp 9 occurs in the genetically distinct, partially sequenced collagens of type I, II, I I I 10, in less well-characterized collagenoid components of base ment membranes ("type IV" 11) and of human placenta12, in the subcomponent C l q 13,14 of the first component Cl ( = C lq, C lr, C ls; "C lt" sug gested) 15,16 of complement17, in elastin 18, 19 , and in a protein of bone that contains 4-carboxyglutamyl residues, binds to hydroxyapatite via Ca2+ and could be a fragment of procollagen 20.
In collagen molecules, the constant Hyp-content is the decisive parameter that determines the thermal stability of their classical triple helical, pepsin re sistant in vivo structure: the thermal transition of the helical conformation in unhydroxylated mole cules is 15 °C lower than in hydroxylated mole cules, 24 °C versus 39 °C 21_25.
In Clq, a collagenase digestable, pepsin resistant sequence of 78 residues is arranged in 26 repetitive units of the collagen triplet type 13,14>143. The simi larity of C lq and collagen is also borne out by these proteins' ability to interact with DNA 26, 27 and by their competition for specific binding sites on sensi tized erythrocytes and immune complexes 28, 29, or on human platelets 30, 81>139. Based on these chemical and biological findings, we assume that the triple helical structure within C lq 32 is also dependent on the Hyp-content under physiological conditions. Both collagens and C lq can be produced and secreted by fibroblasts 33, and possess the repetitive triplet unit -X-Y-Gly-10,13. The occurrence of Hyp is restricted to the N-terminal position next to gly cine, i. e. to the sequence -X-Hyp-Gly-10,13.
The enzyme prolyl hydroxylase (E.C. 1.14.11.2) is responsible for the post-translational conversion of -X-Pro-Gly-to -X-Hyp-Gly-34-46.
The enzyme belongs to a group of 2-oxoglutaratecoupled oxidoreductases occuring in man, animals, plants, microorganisms 36; it needs a reducing agent, and its non-heme Fe2+ is directly involved in the catalytic action39. The enzyme utilizes molecular oxygen, introducing one atom into the substrate peptidyl proline at C4 in trans position, and the other one into 2-oxoglutarate at C2 leading to de-carboxylation and formation of succinate38; its sub strate specificity requires polypeptides of the phy siological (X-Pro-Gly)n structure, with n = 1,2 . . . 38, and among non-physiological polypeptides, only (X-Pro-/?-Ala) "-chains are hydroxylated, indicating a subordinate significance of C l within the glycyl residue 42.
The enzyme occurs in various tissues 35, 40, and its subcellular location is restricted to the cisternae of the rough endoplasmic reticulum 38; its activity is a marker for fibrogenesis: during periods of both physiologically or pathologically intensified collagen metabolism, e. g. embryonic morphogenesis43, fi brosis of lung44 and liver46, marked increases pre cede and parallel the formation of connective tissue. The human enzyme has been purified from foetal skin and from a mixture of foetal tissues by affinity chromatography 41.
Hypothesis
We postulate that a non-sedative metabolite of thalidomide causes diminution of prolyl hydroxylation by direct inhibition of prolyl hydroxylase. The effect of the sedative parent compound (Fig. 1, I ) on the activity of the enzyme has been studied without interpretable results 47. indicates differences in embryotoxicity: benzamide derivatives are less effective than o-carboxybenzamide compounds. A planar aromatic structure is indispensible for the embryopathic effects78, 2-hexahydrophtalimido-glutarimide and 2-succinimido-glutarimide are not teratogenic 141. Definite structure-function relations for R are not established 79.
The non-sedative hydrolysis product in question is 4-(o-carboxybenzamido) L-glutaramic acid (Fig.  1, II) . It mimics conformation and configuration of the tripeptide Pro-Pro-Gly (Fig. 3) After binding, II is believed to form a complex with the enzyme-bound Fe2+ via its carboxyl group in the glutamic acid side chain {cf. Figs 2 , 3 ) , thus blocking the binding and catalytic site of the enzyme. The distance x between the iron atom and C4 within the appropriate prolyl residue was as sumed to be 3.5 Ä ^ x 5^ 4.5 Ä on grounds of the size of the oxygen substrate, x can easily be bridged by the carboxyl group mentioned above, provided that the positions of C3 and C4 in the prolyl and glutamyl residues are identical. The conformation of H-Pro-Pro-Gly-OH and Pht-Glu-NH2 we assume on the basis of covalent-and van der Waals-radius is in agreement with the conformation of the hor-* In an additional paper (V. Günzler, H. Hanauske-Abel, in preparation) we will provide details of an independent hy pothesis concerning the catalytic mechanism of 2-oxoglutarate-coupled oxidoreductases: in brief, we propose that both the oxygen molecule and the 2-oxoglutarate mole cule bind to a non-heme iron atom affixed to the protein.
This produces an arrangement simultaneously facilitating decarboxylation and cleavage of the 0 -0 bond. Our contention is in agreement with the known structural, stoichiometric and kinetic data of these enzymes. This hypothesis implies that the sequence -X-GluGly-, since it also might be inhibitory, is not com mon in the natural peptide substrates of prolyl hy droxylase.
Collagen type I is the only large Hyp-containing protein whose primary structure is sufficiently wellknown for examination of this deduction. Checking the amino acid sequence of its a l and a2 sub units 10, 54, each one comprising more than 1000 res idues, one finds 62 Glu residues occur in position X of the -X-Y-Gly-triplets, but only 9 in position Y. Asp residues, thought isofunctional with Glu residues in terms of protein-chemical features, exhibit a X/Y distribution of 19/21.
Discussion
In man, thalidomide causes a specific embryo pathy that amounts to a phenocopy of the dominant Oram-Holt syndrome combined with the recessive Fanconi panmyelopathy 55, 56. Collagens are integral parts of all connective tis sue structures 57,58. They play a crucial role not only in scarring137, in perfect parenchymal re generation after in ju ry 59 and in cell orientation60, but also in cell differentiation and organ develop ment during embryonic morphogenesis as demon strated in vivo for ossification via an enchondral sequence and in culture for myogenesis 61~64. Col lagen molecules lacking the Hyp-dependent triple helical structure under physiological conditions, are not released at a normal rate by collagen synthe sizing cells: in culture, the secretion of Hyp-deficient non-triple helical collagen precursors is markedly reduced or completely stopped by a conformationdependent barrier within these cells 21, 38, 65-69; in developing chick embryos, this retardation produces deformation of the lim bs70 and arrest of collagen accumulation71; in experimental cirrhosis, it di minishes the formation of collagen, and the lesser degree of fibrosis is accompanied by an improvement of liver function 72.
On the background of these findings, inhibition of prolyl hydroxylase and subsequent delay of col lagen secretion can be expected to have distinct ef fects at least during periods of physiologically or pathologically intensified collagen metabolism.
Concerning embryonic morphogenesis, we anti cipate the emergence of a complex clinical syn drome with various congenital anomalies com prising the entire width from agenesis of parts of the body to dysgenetic changes in their normal macroscopic and microscopic appearance. The ex tent and type of these malformations obviously depend on start, duration, dosage of drug adminis tration to the mother. The non-hereditary alterations will affect supporting structures and parenchymal organs of the baby, involve both sexes in the same ratio, and follow a bilateral pattern of symmetry, as far as the enchondral osteogenesis in the limbs, e. g. the long tubular bones, is disturbed.
The thalidomide embryopathy 73,74 conforms to this clinical syndrome.
The teratogenic action of thalidomide maeroscopically and microscopically affects numerous parts of the body 73, 74 and is restricted to a short period of morphogenesis 74, 75. In experimental ani mal, subperiostal osteogenesis histologically ap peared normal, enchondral osteogenesis, however, was markedly disturbed during chondrogenesis and osteogenesis. Chondrocytes displayed unusual ar rangement, intracellular granules and, generally, mesenchymal derivatives were particularly suscep tible 76,77. The peptide substrate of prolyl hy droxylase bears a structural resemblance not only to the conformation of II but also to the configuration of embryopathic thalidomide analoga: the position of the indispensible planar structure in these sub stances (Fig. 1, III) corresponds to the nearly planar N-terminal ring of the mimicked -Pro-ProGly-sequence (Fig. 3) .
Concerning chronic diseases characterized by col lagen accumulation in the affected tissues, we com municate a clinical observation in one patient suf fering from pulmonary fibrosis (sarcoidosis of the lung) : administration of the drug produced im provement of the pulmonary function. "Unter der Wirkung von K 17 verringerte sich das SauerstoffDefizit, so daß der Patient für längere Zeit auf die Sauerstoff-Flasche verzichten konnte" ** 80.
Due to the metabolite II, the thalidomide embryo pathy unintentionally provides an experimental model of selective fibrosuppression in man testifying to the potentials of such pharmacologic treatment which is disastrous to the developing embryo and comparable to the oral anticoagulants as to teratogenity 81_83.
It is reasonable to use drugs that interfere with structure and secretion of collagens in all patho logical conditions aggravated by fibrosis and scar ring 84.
In man, " thalidomide is the most effective drug and in appropriate dosage can completely suppress ENL" 85, erythema nodosum leprosum.
ENL originates in patients fallen ill with the lepromatous form of leprosy, and by the end of the first year of anti-leprosy treatment, about 50% of such patients have experienced at least one episode of E N L 106" 111.
Although it appears to be a tropical curiosity by West European standards, the histopathological findings in biopsy specimen of skin taken from acute ENL lesions document that its pathogenic mechanism is a prototype of immunological tissue damage: all the hallmarks of the Arthus reaction, an acute intense inflammatory lesion of skin that depends on antibody mediated complement acti vation 112 and can be initiated by the classical pathway113-116, are evident in light and immuno fluorescence microscopy85,117~119, and therefore acute ENL can be interpreted as a probe of comple ment activity.
The subcomponent C lq of the first component Cl of human complement links this system to the immunoglobulins and thereby triggers and trains the classical pathway 11.
Its activation has a causal connection to here ditary angioedema86 and to the effects of certain ** K 17 ( = thalidomide) decreased the oxygen deficit, so that the patient could do without administration of oxy gen for longer periods. Fig. 4 .
Selective destruction of the collagen-like parts within C lq molecules, the N-terminal sector and the , followed by a C-terminal noncollagenous region of 103 -108 residues in globular arrangement (c). Side-byside association of N-terminal triple helical monomer parts occurs covalently during dimer and non-covalently during hexamer formation, producing a collagen microfibril-like sector (d). This sector is linked by the unassociated C-ter minal triple helical monomer parts, the connecting strands, to the globular regions 32>136. These interact with immune complexes via the Fc portions of IgG and IgM antibodies, whereupon a critical conformational change in the collagen microfibril-like_sector (d) activates Clr, which in turn con verts Cls to Cls, triggering the complement cascade 17. The allosteric rearrangement within d also is the prerequisite to activation by a Clr-independent interaction of Cls and Clq 15. In this manner, the structure of Clq is fundamental for the release mechanism of the classical pathway of com plement.
connecting strands, abolishes the capacity to ac tivate C lr and Cls and to trigger the classical path way cascade, but does not abolish the capacity of immune complex binding 105,144. The action of II will selectively affect the col lagen-like parts of C lq in a similar way. Provided that there is no conformational barrier within C lq synthesizing cells blocking the extrusion of the Hvpdeficient non-triple helical molecules, II will lead to the appearance of structurally and functionally impaired C lq in the serum, which we term "C lq II". We surmise that, due to their distorted conforma tion, these molecules lade the capacity to activate C lr and Cls. Consequently, a substitution of C lq II for C lq renders the first component useless and paralyses the classical pathway cascade, whose proteolytic activation yields fragments and cul minates in membrane damage and cell death17,112; these fragments mediate the chemotactic attraction and enhance the phagocytic ability at least of poly morphonuclear leucocytes, evoke a histamine-depen dent edema and hyperemia reaction, and exert histamine-independent effects on the microvascu lature, e. g. smooth muscle contraction. It is of preeminent importance that C lq II for these reasons will act as a selective suppressor of acute, classical pathway mediated inflammations: because of its strategic position 15, it will prevent the complementdependent cytolysis and the formation of the strong ly phlogogenic fragments.
In acute and persistent ENL, thalidomide has no antibacterial effect 12°, its mode of action is un known, its impressive efficacy established106' 121~128.
Concerning treatment of acute ENL, no changes of the clinical symptoms occur during at least the first 36 hours after administration of the drug. On the end of the second day, various pathological findings start to ameliorate and on the following days return to normal.
There is a fall in fever, a reduction of the en larged lymph nodes, a resorption of the sub cutaneous nodules with decrease in size, erythema, tenderness, and even ulcerating lesions improve markedly. In biopsy specimen, polymorphonuclear leucocyte infiltration, hyperemia, edema, and other signs of acute inflammation disappear.
Upon withdrawal of thalidomide, relapse of ENL occurs after few symptom-free days: at the begin ning, the recurring reactions are mild, but within days progress to the severe stage.
We argue that these effects are caused by disap pearance and reappearance of subcomponent C lq, or of adequately functioning component C l, respec tively.
Concerning treatment of persistent ENL, the un interrupted use of thalidomide over a period of years does not cripple immunologic defence against bacteria, fungi, viruses, and does not render these thalidomide-dependent patients vulnerable to infec tions. Hence our hypothesis makes it necessary to suppose that a protracted selective pharm acologic deficiency of the classical pathway due to silenced C l, is not associated with an increased susceptibility to bacterial, fungal, viral infections. Genetic defi ciencies of the early components of the classical pathway 129_132>138 support this deduction.
Patients with these hereditary abnormalities " do not have an unusual susceptibility to infections, they illustrate how unimportant the classical pathway is for defense against the usual variety of Gram-nega tive and Gram-positive bacilli. In vitro, it is easily shown that bactericidal activity with unsensitized bacteria is normal, and with sensitized bacteria, markedly deficient" 133.
Due to the metabolite II, the thalidomide therapy of ENL unintentionally provides an experimental model of both selective immunosuppression and partial immunoprophylaxis in man, testifying to the potentials of such pharmacologic treatment which does not disarm the immune system of a patient and does not extradite him to bacteria, fungi, viruses, malignant tumors in complete contrast to the con temporary exercise of immunosuppression.
It is reasonable to use drugs that interfere with structure and function of C l in all pathological con ditions aggravated by activation of the classical pathway of complement134.
We will not dwell here on further, less important evidence supporting this hypothesis. Systematic studies in drug design can be expected to produce specific inhibitors of other enzymes performing posttranslational modifications, e. g. the lysyl hydroxy lase 135, and to decide whether the calculated in ter ference w ith the function of specific molecules b y disturbing the form ation of their physiological structure w ithout inhibiting precursor biosynthesis, adds novel instruments to the tool-box of thera peutics.
We wish to express our deep esteem of the late Dr. Heide, who generously granted us unrestricted use of the library of the Behringwerke AG, Marburg, and complete access to the computerized internal literature service of the Farbwerke Hoechst AG, Frankfurt. We are indebted to Prof. Karlson and Prof. Wiegandt for their help in preparing this manuscript; it was proofread by Dr. Nawrocki and typewritten by Mrs. Ballach. Mr. Weber, department head of the Zentralbibliothek der Medizin, Universitäts-und Staatsbibliothek, Köln, kindly met our wishes.
A ddendum
Pilot studies at the Departments of Dermatology and Pathology, Royal University, Guardamangia/ Malta, at the Department of Medical Microbiology, Johann Gutenberg Universität, Mainz/FRG, at the Department of Medical Biochemistry, University of Oulu/Finland, yielded preliminary results that seem to conform to our hypothesis:
In sera of ENL patients on thalidomide, C lq activity was reduced relative to the activity in sera of healthy persons and in serum of one patient suf fering from a mild form of acute ENL; in vitro, II is an inhibitor of prolyl hydroxylase activitywhether II acts by the mechanism we suggest, is under scrutiny.
Thanks are due to Dr. Bonnici, Guardamangia, who supplied the ENL sera; to Dr. Pullicino, Guar damangia, who placed the serological laboratory at H.H.-A.'s disposal; to Prof. Loos,Mainz, who re determined and affirmed the hemolytic complement activity and who measured the C lq activity of the ENL sera; to Prof. Kivirikko, Oulu, who tested the effect of synthetic II on the pure enzyme.
The extent of their cooperation, and the en couragement and assistance of those unnamed do not go without mention and cannot be over emphasized.
